135 related articles for article (PubMed ID: 15228675)
1. [Computer aid design of antisense oligonucleotide in gene therapy--review].
Wu QW; Wu JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Jun; 12(3):387-91. PubMed ID: 15228675
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
3. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
[TBL] [Abstract][Full Text] [Related]
4. Liver as a target for oligonucleotide therapeutics.
Sehgal A; Vaishnaw A; Fitzgerald K
J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
[TBL] [Abstract][Full Text] [Related]
5. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
6. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
Spiller DG; Giles RV; Broughton CM; Grzybowski J; Ruddell CJ; Tidd DM; Clark RE
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):281-93. PubMed ID: 9743466
[TBL] [Abstract][Full Text] [Related]
7. Antisense anticancer oligonucleotide therapeutics.
Wang H; Prasad G; Buolamwini JK; Zhang R
Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
[TBL] [Abstract][Full Text] [Related]
8. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
9. Theoretical and experimental approaches to design effective antisense oligonucleotides.
Sczakiel G
Front Biosci; 2000 Jan; 5():D194-201. PubMed ID: 10702382
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides in cancer.
Castanotto D; Stein CA
Curr Opin Oncol; 2014 Nov; 26(6):584-9. PubMed ID: 25188471
[TBL] [Abstract][Full Text] [Related]
11. Technical improvements in the computational target search for antisense oligonucleotides.
Far RK; Leppert J; Frank K; Sczakiel G
Oligonucleotides; 2005; 15(3):223-33. PubMed ID: 16201910
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide therapeutics for human leukemia.
Gewirtz AM
Crit Rev Oncog; 1997; 8(1):93-109. PubMed ID: 9516088
[TBL] [Abstract][Full Text] [Related]
13. Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design.
Delihas N; Rokita SE; Zheng P
Nat Biotechnol; 1997 Aug; 15(8):751-3. PubMed ID: 9255788
[TBL] [Abstract][Full Text] [Related]
14. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide therapy in the management of bladder cancer.
So A; Rocchi P; Gleave M
Curr Opin Urol; 2005 Sep; 15(5):320-7. PubMed ID: 16093856
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of antisense oligonucleotide interaction with natural RNAs.
Serikov R; Petyuk V; Vorobijev Y; Koval V; Fedorova O; Vlassov V; Zenkova M
J Biomol Struct Dyn; 2011 Aug; 29(1):27-50. PubMed ID: 21696224
[TBL] [Abstract][Full Text] [Related]
17. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
Kronenwett R; Haas R; Sczakiel G
J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
[TBL] [Abstract][Full Text] [Related]
18. Antisense tumor therapy (a dream under construction).
Kopper L; Kovalszky I
In Vivo; 1994; 8(5):781-6. PubMed ID: 7727725
[TBL] [Abstract][Full Text] [Related]
19. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Vaerman JL; Lewalle P; Martiat P
Stem Cells; 1993 Oct; 11 Suppl 3():89-95. PubMed ID: 8298481
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
